Table 1.
Baseline demographic, clinical, and biochemical characteristics of CRIC Study participants without HF at baseline by category of hsTnT
| Characterisitics | hsTnT categories (n), pg/mla | P Value | ||||
|---|---|---|---|---|---|---|
| ≤5 (n=814) | >5–9.3 (n=668) | >9.3–15.0 (n=667) | >15.0–26.5 (n=667) | >26.5 (n=667) | ||
| Age, yr | 52.6 (11.8) | 56.8 (11.3) | 60.8 (9.9) | 61.1 (9.6) | 59.3 (10.4) | <0.001 |
| Women | 556 (68.3%) | 348 (52.1%) | 278 (41.7%) | 234 (35.1%) | 171 (25.6%) | <0.001 |
| Race/ethnicity | <0.001 | |||||
| Non-Hispanic white | 417 (51.2%) | 326 (48.8%) | 310 (46.5%) | 262 (39.3%) | 177 (26.5%) | |
| Non-Hispanic black | 280 (34.4%) | 252 (37.7%) | 247 (37.0%) | 288 (43.2%) | 326 (48.9%) | |
| Hispanic | 76 (9.3%) | 58 (8.7%) | 84 (12.6%) | 93 (13.9%) | 144 (21.6%) | |
| Other | 41 (5.0%) | 32 (4.8%) | 26 (3.9%) | 24 (3.6%) | 20 (3.0%) | |
| eGFR, ml/min per 1.73 m2b | 56.9 (18.6) | 49.3 (16.0) | 44.8 (12.8) | 40.5 (13.8) | 34.8 (12.3) | <0.001 |
| 24-hour urine protein, g/d | 0.09 (0.06–0.3) | 0.1 (0.06–0.5) | 0.1 (0.07–0.6) | 0.3 (0.09–1.2) | 0.9 (0.2–3.3) | <0.001 |
| Diabetes | 166 (20.4%) | 223 (33.4%) | 322 (48.3%) | 373 (55.9%) | 531 (79.6%) | <0.001 |
| History of MI/stroke/PAD | 94 (11.5%) | 143 (21.4%) | 178 (26.7%) | 243 (36.4%) | 252 (37.8%) | <0.001 |
| Current smoker | 112 (13.8%) | 84 (12.6%) | 85 (12.7%) | 81 (12.1%) | 86 (12.9%) | 0.92 |
| Alcohol use | 591 (72.6%) | 444 (66.5%) | 432 (64.8%) | 401 (60.1%) | 362 (54.3%) | <0.001 |
| Body mass index, kg/m2 | 30.9 (7.9) | 31.3 (7.5) | 32.0 (7.8) | 32.9 (7.8) | 32.6 (7.4) | <0.001 |
| Systolic BP, mmHg | 119.0 (16.9) | 124.8 (19.7) | 129.4 (20.5) | 131.9 (23.1) | 139.1 (24.4) | <0.001 |
| Diastolic BP, mmHg | 71.8 (11.3) | 72.5 (12.0) | 71.4 (12.7) | 71.1 (13.3) | 72.8 (13.8) | 0.08 |
| Hemoglobin, g/dl | 13.0 (1.6) | 13.0 (1.8) | 12.8 (1.8) | 12.4 (1.7) | 11.8 (1.6) | <0.001 |
| LDL cholesterol, mg/dl | 110.6 (34.3) | 103.7 (32.8) | 101.1 (33.0) | 100.3 (36.5) | 102.1 (38.9) | <0.001 |
| HDL cholesterol, mg/dl | 52.4 (16.7) | 48.8 (15.0) | 47.4 (15.4) | 44.5 (14.0) | 45.7 (15.1) | <0.001 |
| ACE/ARB use | 423 (52.5%) | 457 (68.8%) | 469 (70.6%) | 509 (76.8%) | 484 (73.3%) | <0.001 |
| Diuretic use | 299 (37.1%) | 336 (50.6%) | 391 (58.9%) | 442 (66.7%) | 480 (72.7%) | <0.001 |
| β-Blocker use | 251 (31.1%) | 282 (42.5%) | 323 (48.6%) | 360 (54.3%) | 375 (56.8%) | <0.001 |
| FGF23, RU/ml | 107.7 (74.6–166.0) | 121.6 (85.8–194.1) | 138.6 (96.6–215.9) | 152.9 (103.4–239.4) | 198.0 (128.5–334.8) | <0.001 |
| Serum phosphorus, mg/dl | 3.6 (0.6) | 3.6 (0.6) | 3.6 (0.6) | 3.7 (0.6) | 4.1 (0.8) | <0.001 |
| Total PTH, pg/ml | 41.0 (30.0–61.2) | 45.9 (31.5–70.0) | 48.8 (33.0–78.0) | 61.0 (39.2–93.2) | 79.8 (46.0–136.0) | <0.001 |
| EF from echocardiogramc | 56.0 (6.4) | 55.9 (6.8) | 55.4 (7.4) | 54.2 (8.3) | 52.9 (8.3) | <0.001 |
| LVMI, g/m2.7c | 45.0 (10.4) | 47.1 (10.9) | 51.1 (12.5) | 54.7 (14.0) | 59.2 (14.4) | <0.001 |
MI, myocardial infarction; PAD, peripheral arterial disease; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; RU, relative units.
a
Detectable levels of hsTnT were divided into quartiles.
b
eGFR calculated using serum creatinine and cystatin C (47).
c
From the year 1 clinic visit.